The application of 3D printing in medicine is developing very rapidly, and the benefits this technology brings to patients are obvious to all. In addition to dentistry and orthopedics, more and more medical fields are beginning to study 3D printing technology . Recently, a 3D bio-printing technology for regenerative medicine, cell therapy and human tissue of newborn baby clothes began to subvert the medical profession.
It is well known that when a baby is born, it will carry the amnion on the placenta. But what many people may not be aware of is that the amniotic membrane contains a large number of human stem cells. In the past, this placenta that was made to make it less pleasant was discarded as garbage. But Chicago-based startup AmnioChor sees it as a huge gold mine, hoping to recycle unused human stem cells from newborns' fetus and use it in regenerative medicine, cell therapy, and human tissue. 3D bioprinting, etc.
In fact, this idea is not new. At present, many hospitals and institutions all over the world have set up cord blood banks to collect cord blood of newborns. The reason is also to recover mature stem cells, and then use them for treatment and treatment. Blood-related genetic diseases, or used by researchers to develop cell-based therapeutic drugs and medical devices. Family members can also consider paying to deposit cord blood into their own name in case their children need to be treated with stem cells.
The method introduced by AmnioChor last year goes even further. The recycling range is not limited to cord blood. The model of AmnioChor is frozen intact amniotic membrane, including mesenchymal and epithelial stem cells or amnion derived stem cells (ADSC), and then The person can't find it in the cord blood. Furthermore, in addition to being used in regenerative medicine and cell therapy, the company emphasizes that these cells are well suited for final bioprinting of organs. In fact, many laboratories use mesenchymal cells when studying bioprinting technology.
In order to capture amniotic material, AmnioChor is currently developing a kit called AmnioCept, which is currently in the third prototype phase. In practice, the company's team will bring AmnioCept into the operating room to recycle the material and return it to the OmniBank facility for storage. This process is very similar to the operating mode of the cord blood bank. According to Med City News, AmnioChor is seeking a partnership with hospitals that have not signed a cord blood contract.
AmnioChor's amniotic membrane storage technology was developed by Dr. Dale Woodbury and Dr. Akiva Marcus at the Ira B. Black Stem Cell Research Center, Department of Neuroscience and Cell Biology, Robert Wood Johnson School of Medicine, which is now part of Rutgers University. . AmnioChor has an exclusive license for this technology and has received a seed funding from the New Jersey Musculoskeletal Transplant Foundation (MTF) for commercialization.
SHENZHEN 4IN1 ELECTRONIC TECHNOLOGY CO.LTD , https://www.siheyidz.com